Nephrology
Original Research
Chronic Kidney Disease and Military Service in US Adults, 1999-2018
This observational study used National Health and Nutrition Examination Survey data to quantify the association between CKD and military service...
News
Low-dose methotrexate carries higher risk for older patients with CKD
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
Conference Coverage
Dietary nitrates reduce contrast-induced nephropathy in ACS
“Currently, aside from intravenous hydration, there is no proven treatment that reduces contrast-induced nephropathy. We feel that dietary...
Latest News
Medicare announces 10 drugs targeted for price cuts in 2026
People on Medicare may in 2026 see prices drop for 10 medicines, including pricey diabetes, cancer, blood clot, and arthritis treatments.
News
Better than dialysis? Artificial kidney could be the future
We see it initially as a bridge to transplantation, or as a better option than dialysis for those who will never get a transplant.
Conference Coverage
Strategies for complete B-cell depletion evolve for patients with lupus nephritis
Growing evidence suggests more complete B-cell depletion in patients with lupus nephritis is associated with a greater likelihood of treatment...
Conference Coverage
Lupus nephritis: Hopes, questions arise for baricitinib
Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of...
News
FDA approves new drug, sotagliflozin, for heart failure
“It will be a reasonably tall task for sotagliflozin to come from behind and be disruptive in a space where there are already two well-established...
Conference Coverage
Early remission in lupus nephritis can still progress to advanced CKD
Patients with lupus nephritis who achieve complete remission within 1 year of starting treatment can still progress to advanced chronic kidney...
Latest News
CKD Screening in all U.S. adults found cost effective
Modeling showed screening for and treating chronic kidney disease in U.S. adults was cost effective now that SGLT2 inhibitors are available.